CLINICAL_TRIALS
withdrawal
· 2016-03-03
Clinical Trial Update: A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer [NA]
Summary
This clinical trial (NCT02307474) evaluating SBRT with adjuvant pazopanib for renal cell carcinoma has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Case Comprehensive Cancer Center | Conditions: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma | NA | Status: WITHDRAWN